Head-to-head · free
Novartis AG vs PDS Biotechnology Corporation
NVS vs PDSB — return on capital, cash generation, margins and balance sheet side by side.
NVS
1 / 2
measures where NVS leads
PDSB
1 / 2
measures where PDSB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | NVS | PDSB · FY2025 |
|---|---|---|
| Revenue | — | — |
| Net income | — | (8.5M) |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | — | (27.8M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | 18.6% | — |
| Return on equity | 31.0% | -244.2% |
| Gross margin | 75.8% | — |
| Operating margin | 31.1% | — |
| Net debt / EBITDA | 0.96x | 0.31x |
Figures are as reported by each company; latest fiscal year shown.
Where PDS Biotechnology Corporation's cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free